Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1 Study of SEA CD70 in Myeloid Malignancies
NCT Number:
NCT04227847
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Myeloid and Monocytic Leukemia
Study Objectives:
This is a phase 1, open-label, multicenter, dose-escalation, and cohort expansion study designed to evaluate the safety, tolerability, PK, and antitumor activity of SEA-CD70 in adults with myeloid malignancies. The study will be conducted in up to 3 parts.
Part A is a dose escalation cohort designed to identify the MTD or recommended expansion dose of SEA-CD70 in subjects with relapsed/refractory (HMA-failure) MDS. Part B is an expansion cohort designed to evaluate the safety and tolerability of SEA-CD70 in subjects with relapsed/refractory (HMA-failure) MDS. Part C is an expansion cohort designed to evaluate the safety and tolerability of SEA-CD70 in subjects with relapsed/refractory AML.
Study Documents
(MUSC NetID required for document access)